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ABSTRACT 
Background:  A survey was developed to gather information from both pharmacists and patients with epilepsy 
on the issue of antiepileptic drug formulation switching.  This study looked at the patient-focused issues 
associated with switching among various forms of the same antiepileptic drug.  This switching includes brand to 
generic, generic to brand and also generic to generic.  Finding the right dose of the optimal treatment to prevent 
seizures in some patients with epilepsy is a complex and sometimes lengthy process.  Formulation switching 
with antiepileptic drugs may have undesirable results such as an increase in seizure activity or an increase in 
adverse events.  Education for the patient and the many healthcare professionals involved with the care of the 
patient with epilepsy is an important aspect of this issue.  Since medication plays a major role in the treatment 
of epilepsy, pharmacists serve an important function in the health care of patients with this chronic disease.  
Pharmacists should take advantage of the opportunity to expand their roles in providing optimal care to their 
patients with epilepsy.  Reporting adverse drug reactions with antiepileptic drug formulation switching through 
the FDA’s Safety Information and Adverse Event Reporting Program (MedWatch, www.fda.gov/medwatch) is 
an example how this expansion can be achieved.  
 
Purpose:  The goal of this educational project was to assess patient and pharmacist knowledge of and attitude 
toward antiepileptic drug formulation switching and reporting of adverse drug reactions in patients with 
epilepsy.   
 
Methods:  We asked both pharmacists (n=500) and patients (n=250) to respond to a brief survey via the mail 
(pharmacists) or online (patients with epilepsy).  The online survey on Zoomerang® was open for 6 weeks.   
Results:  Data was obtained from 112 pharmacists and 82 patients (or parents of patients) with epilepsy.  Nearly 
all respondents (>98%) agreed that finding the right dose of the right drug to prevent seizures can sometimes be 
difficult and take awhile.  More than 85% of pharmacists and 92% of patients agreed that switching between 
forms of the same antiepileptic drugs may cause an increase in seizures or side effects.  Nearly half (49%) of 
pharmacists knew of patients who have described problems when they have changed antiepileptic drug 
formulations.  Similar numbers were reported by patients for themselves (41%) or a friend (48%).  More than 4 
out of 10 pharmacists (41%) and patients (45%) knew that situations involving patients experiencing problems 
with formulation switching should be reported as adverse drug events.  Most pharmacists (75%), but less than 
half of patients (45%), knew that problems with switching between the same forms of antiepileptic drugs should 
be reported as adverse drug events.  Most pharmacists (79%), but very few patients (6%), knew about the 
MEDWATCH program before the survey.  While 27% of pharmacists reported using the MEDWATCH 
program, only one of them used it to report a patient experiencing problems with formulation switching.  In our 
sample, only one patient out of 82 reported using the MEDWATCH program and this was for reporting 
problems with formulation switching.  Both pharmacists and patients were more willing to learn about and use 
the MEDWATCH program after completing the survey.   
 
Conclusion:  We conclude that both pharmacists and patients with epilepsy are under-informed and under-
involved with reporting adverse drug reactions.
BACKGROUND 
Epilepsy is a common neurological problem affecting 1-2% of the United States population.  Epilepsy 
has significant economic and social consequences.  These can be minimized by optimal seizure control.  
Antiepileptic drugs (AEDs) are the mainstay of treatment in this chronic disease.  Treatment goals for patients 
with epilepsy include the prevention of seizures, the reduction and/or prevention of adverse effects and drug 
interactions, improvement of quality of life and patient satisfaction.1   
This project focuses on the patient-focused issues associated with switching among various forms of the 
same AEDs.  This switching includes brand to generic, generic to brand and also generic to generic.  Finding 
the right dose of the optimal treatment to prevent seizures in some patients with epilepsy is a complex and 
sometimes lengthy process.  Formulation switching with AEDs can have undesirable results such as an increase 
in seizure activity or an increase in adverse events.  Seizures have the potential to be life threatening, and can 
endanger the individual and others, particularly if they occur without warning or while the individual is engaged 
in the various activities of daily living.  Hence, to risk the occurrence of seizures or adverse events by switching 
products is a matter of both public and individual safety.  Though many exist now, a number of currently 
available AEDs will be available in generic formulations in the near future. 
Because of the FDA’s designation of drugs as bioequivalent, some believe that different formulations of 
the same product are entirely equivalent and interchangeable.  This may be an accurate statement for many drug 
products on the market, but studies have documented that the FDA’s acceptable therapeutic range for different 
formulations of AEDs may be too broad for some patients with epilepsy.  Differences do exist and these 
differences may result in breakthrough seizures, unacceptable adverse drug reactions and, in turn, increased 
expense to the individual and to society.2
Of particular concern is the rate and extent of absorption (bioavailability) between different 
formulations.  The plus 25% and minus 20% (80-125 rule) allowed by the FDA for variance in bioequivalence 
may result in lower concentrations with resultant seizures or higher concentrations and subsequent toxicity 
(Figures 1a & b).  Many epilepsy patients do not tolerate such variability.  Uncertainty about when seizure 
activity may occur is omnipresent in many patients’ lives.  Formulation switching can add to that uncertainty.  It 
is our opinion that adverse drug reactions (either seizures or toxicity) from AED formulation switching go 
under-reported by both patients and healthcare professionals. 
 Education for the patient and the many healthcare professionals involved with the care of the patient 
with epilepsy is an important aspect of this issue.  Since medication plays the major role in the treatment of 
epilepsy, pharmacists serve an important function in the health care of patients with this chronic disease.  
Pharmacists should take advantage of the opportunity to expand their roles in providing optimal care to their 
patients with epilepsy.  Reporting adverse drug reactions with AED formulation switching through the FDA’s 
Safety Information and Adverse Event Reporting Program (MedWatch, www.fda.gov/medwatch) is an example 
how this expansion can be achieved.   
We developed a survey instrument to gather information from both pharmacists and patients on this 
issue.  Our goal of this educational project was to assess both populations’ knowledge of and attitude toward 
AED formulation switching and reporting of adverse drug reactions. 
 
METHODS 
This is a cross-sectional, descriptive study asking both pharmacists and patients to respond to a brief 
survey.  Biomedical Institutional Review Board (IRB) approval was obtained and a waiver of consent granted. 
Patient Survey 
Patients or parents of patients with epilepsy were recruited from the Epilepsy Foundation of Central 
Ohio’s database.  A 21-question survey was uploaded onto Zoomerang® (www.zoomerang.com).  The survey 
began with a cover letter defining switching forms of the same medication as, “1. Switching from a brand name 
to a generic drug, 2. Switching from a generic to a brand name drug, or 3. Switching from one generic to 
another generic drug.”  The survey was confidential and voluntary.  The first 13 questions asked about their 
knowledge of and attitudes towards switching between forms of the same antiepileptic drugs and reporting 
adverse reactions when switching formulations.  The last 8 questions were related to demographic information 
and the number of generic and brand name antiepileptic drugs they were currently using.  Emails with a link to 
the Zoomerang survey were sent to 250 patients and the survey site was left open for 6 weeks.   
Pharmacist Survey 
Five-hundred Ohio pharmacists were randomly selected from the Ohio State Board of Pharmacy’s 
database of registered pharmacists by randomly choosing 125 from each of the four community pharmacy 
practice types (independent community pharmacy, small chain, large chain, and clinic or medical center).  The 
pharmacists were mailed a cover letter, a brief 19-question survey and a postage-paid return envelope.  The 
survey was confidential and voluntary.  The cover letter defined drug formulation switching and the potential 
for patients to experience problems.  The first 12 questions dealt with their knowledge of and attitudes towards 
antiepileptic drug formulation switching.  The last 7 questions collected demographic information.  Surveys 
were collected over a six-week period of time. 
Data Analysis 
Descriptive statistics were used to characterize the demographic data and responses by population.  
 
RESULTS 
Data was obtained from 82 patients (or parents) with epilepsy and 112 pharmacists for a response rate of 
33% and 22%, respectively.  Some of the pharmacist surveys were not used due to them no longer living in 
Ohio, because they were no longer practicing pharmacy, they were not practicing pharmacy in one of our 
targeted community pharmacy areas or they came in past the 6 week deadline.  Table 1 provides details on the 
respondent demographics from both populations. 
Table 2 depicts the questions and responses from both patients and pharmacists.  Nearly all respondents 
(>98%) agreed that finding the right dose of the right drug to prevent seizures can sometimes be difficult and 
take awhile.  More than 85% of pharmacists and 92% of patients agreed that switching between forms of the 
same antiepileptic drugs may cause an increase in seizures or side effects.   
As can be seen from Table 3, more than half (51%) of pharmacists knew of patients who have described 
problems when they have changed antiepileptic drug formulations.  Similar numbers were reported by patients 
for themselves (43%) or someone they knew (48%).  Of note, more than one-third of the patient respondents 
reported that this question did not apply to them. 
More than 4 out of 10 pharmacists (41%) and patients (45%) knew that situations involving patients 
experiencing problems with formulation switching should be reported as adverse drug events.  While most 
pharmacists (75%) knew that problems with switching between the same forms of antiepileptic drugs should be 
reported as adverse drug events, this was in contrast to less than half of patients (45%).  Most pharmacists 
(79%), but very few patients (6%), knew about the MEDWATCH program before the survey.  While 27% of 
pharmacists reported using the MEDWATCH program, only one of them used it to report a patient experiencing 
problems with formulation switching.  In our sample, only one patient out of 82 reported using the 
MEDWATCH program and this was for reporting problems with formulation switching.  Both pharmacists and 
patients were more willing to learn about and use the MEDWATCH program after completing the survey.   
 Table 4 summarizes the comments from by patients and pharmacists when asked if they did or did not 
see a role for themselves and why in reporting adverse reactions using MEDWATCH.  As you can see, most of 
the respondents whom provided comments were positive in their responses, though some pharmacists gave 
reasons why they are not willing to use the MEDWATCH system. 
 
Study Limitations 
Our study is not without limitations.  It was a cross-sectional study and thus did not track patients or 
pharmacists responses over time; they were asked their opinions just once.  We did not validate the survey 
questions we developed.  Our response rate for patients (33%) and pharmacists (22%) was less than optimal.  
For the patient population, we were limited to Central Ohio patients and those with internet access.  For the 
pharmacists, we only sampled those from Ohio and thus our data may not be applicable to all pharmacists. 
 
DISCUSSION  
At present, no published data exists in the medical literature, specific to epilepsy, on the attitudes of 
patients and pharmacists on the issue of AED formulation switching.  The high level of distrust among patients 
suggests their experiences with AED formulation switching have not been favorable. 
Suggestions for adoption 
This current survey points to areas where education about MEDWATCH could be targeted.  It would be 
beneficial to engage patients with epilepsy (and their families and caregivers) about the importance of being 
involved in advocacy for themselves and others.  Persons who are motivated to report their adverse experiences 
could be provided with resources explaining how to access MEDWATCH.  The MEDWATCH program has 
both a web-based reporting system and a paper-based system.  Health care professionals and pharmacists 
involved in epilepsy care could easily provide a pamphlet when they encounter patients who have had problems 
from AED formulation switching. 
It is also plausible to think about utilizing advancing technology to allow pharmacists to spend less time 
reporting adverse drug events so they may be more willing to do it.  For example, many hospitals have 
combined MEDWATCH with their own adverse event reporting system to make a more efficient process. 
Pharmacists acknowledge their interest in helping patients as well as their professional role in reporting 
such events.  Educational programs and continuing education credits could be provided to pharmacists.  
Overcoming barriers to reporting adverse events are likely the most important challenge.  Pharmacists in busy 
practices are likely to have time limitations for reporting events.  They may be able to prioritize events for 
reporting.  They may also be able to encourage a greater role for patient involvement in reporting.  
 We conclude that both pharmacists and patients with epilepsy are under-informed and under-involved 
with reporting adverse drug reactions. 
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Table 1.  Respondent Demographics 
 
Patients (n=82)     Mean (SD) 
 
Age of patient      27.1 (17.2) 
Years taking antiepileptic drugs    12.86 (12.88) 
 
Sex 
Men      38% 
Women     57% 
Not reported     5% 
 
# Current AEDs  One   41% 
    Two   38% 
    Three or more  21% 
 
# Current AEDs as Generic Zero   70% 
One   18% 
    Two   4% 
    Three or more  3% 
    Not sure  5% 
 
# Current AEDs as Brand Zero   10% 
One   44% 
    Two   27% 
    Three or more  10% 
    Not sure  9% 
 
 
 
Pharmacists (n=112)     Mean (SD) 
 
Age (years)      47.3 (13.8) 
Years in current practice setting   17.2 (12.3) 
Patients with epilepsy seen per month  20.6 (26.3) 
 
Sex 
 Men      58% 
Women     42% 
 
Practice setting 
Independent Community Pharmacy  38% 
Small Chain     17% 
Large Chain     27% 
Clinic/Medical Building   18% 
 
SD = Standard Deviation 
AED = Antiepileptic Drug 
# = number 
 Table 2.  Comparison of responses by population on questions that were asked of both populations 
 
Survey Questions Patients Pharmacists 
In general, formulation switching with most medications is safe.   
Agree 38 96 
Disagree 62 4 
Finding the right dose of the optimal treatment to prevent seizures in a patient 
with epilepsy can be a complex and sometimes lengthy process. 
  
Agree 99 98 
Disagree 1 2  
Switching between forms of the same antiepileptic drugs may cause an 
increase in seizures OR side effects. 
  
Agree 96 87 
Disagree 4 13 
Did you know that problems with switching between the same forms of 
antiepileptic drugs should be reported as adverse drug events? 
  
Yes 47 41 
No 53 59 
The FDA has a safety information and adverse event reporting program called 
MEDWATCH.  It allows patients to report adverse drug events. Did you 
know about this program before today? 
  
Yes 6 79 
No 94 21 
Have you used the MEDWATCH program?   
Yes 1 27 
No 99 73 
Do you see a role for yourself in reporting adverse drug events through 
MEDWATCH? 
  
Yes 59 88 
No 41 12 
It is estimated that to take 20-40 minutes to fill out a MEDWATCH form.  
Does this fact deter you from using the program? 
  
Yes 33 55 
No 67 45 
After learning more about the MEDWATCH system, are you more or less 
willing to use it? 
  
More 75 85 
Less 25 15 
I am interested in learning more about switching between the same forms of 
antiepileptic drugs. 
  
Yes 50 67 
No 50 33 
I am interested in learning more about the MEDWATCH system.   
Yes 74 68 
No 26 32 
 
Table 3.  Incidence of AED formulation switching problem reported by patients and pharmacists 
 
Population Question Yes No Not 
Applicable 
Patients 
(n=82) 
I have experienced problems when switching between the 
same forms of my antiepileptic drug(s). 
43% 19% 38% 
 I know other patients that have experienced problems when 
switching between the same forms of their antiepileptic 
drugs. 
48% 17% 35% 
Pharmacists 
(n=112) 
Patients with whom I have interacted have described 
problems when they have changed antiepileptic drug 
formulations. 
51% 49%  
 
 
Table 4.  Type and Frequency of comments provided from patients and pharmacists when asked why 
they Do or Do Not see a role for themselves in reporting adverse events through MEDWATCH 
 
Patient Reasons  Frequency 
Advocate for Themselves & Others / Desire to help others  25 
Desire for Heightened Awareness / “Getting the Word Out” 2 
  
Pharmacist Reasons if DID See a Role for Themselves Frequency 
Patient Safety / Increase Awareness of Problems 36 
Pharmacist’s Professional Responsibility / “Right thing to do” 16 
Pharmacist’s ready access to patients 6 
Pharmacist Reasons if DID NOT See a Role for Themselves Frequency 
Too busy 2 
Someone else’s responsibility - not mine, should be patient or physician 2 
Not familiar with MedWatch 2 
Not enough patient information 2 
Too lengthy 1 
Too confusing 1 
 
